Anesthetic preconditioning as endogenous neuroprotection in glaucoma

Tsung Han Chou, Ganeswara Rao Musada, Giovanni Luca Romano, Elizabeth Bolton, Vittorio Porciatti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Blindness in glaucoma is the result of death of Retinal Ganglion Cells (RGCs) and their axons. RGC death is generally preceded by a stage of reversible dysfunction and structural remodeling. Current treatments aimed at reducing intraocular pressure (IOP) are ineffective or incompletely effective in management of the disease. IOP-independent neuroprotection or neuroprotection as adjuvant to IOP lowering in glaucoma remains a challenge as effective agents without side effects have not been identified yet. We show in DBA/2J mice with spontaneous IOP elevation and glaucoma that the lifespan of functional RGCs can be extended by preconditioning RGCs with retrobulbar lidocaine in one eye at four months of age that temporary blocks RGC axonal transport. The contralateral, PBS-injected eye served as control. Lidocaine-induced impairment of axonal transport to superior colliculi was assessed by intravitreal injection of cholera toxin B. Long-term (nine months) effect of lidocaine were assessed on RGC electrical responsiveness (PERG), IOP, expression of relevant protein (BDNF, TrkB, PSD95, GFAP, Synaptophysin, and GAPDH) and RGC density. While lidocaine treatment did not alter the age-related increase of IOP, TrkB expression was elevated, GFAP expression was decreased, RGC survival was improved by 35%, and PERG function was preserved. Results suggest that the lifespan of functional RGCs in mouse glaucoma can be extended by preconditioning RGCs in early stages of the disease using a minimally invasive treatment with retrobulbar lidocaine, a common ophthalmologic procedure. Lidocaine is inexpensive, safe and is approved by Food and Drug Administration (FDA) to be administered intravenously.

Original languageEnglish (US)
Article number237
JournalInternational Journal of Molecular Sciences
Volume19
Issue number1
DOIs
StatePublished - Jan 13 2018

Fingerprint

glaucoma
anesthetics
Anesthetics
preconditioning
Retinal Ganglion Cells
Lidocaine
Glaucoma
intraocular pressure
Intraocular Pressure
cells
Axonal Transport
Synaptophysin
death
Cholera Toxin
Brain-Derived Neurotrophic Factor
Cell death
mice
cholera
Neuroprotection
blindness

Keywords

  • Glaucoma
  • Lidocaine
  • Mouse
  • Neuroprotection
  • Retinal ganglion cells

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Anesthetic preconditioning as endogenous neuroprotection in glaucoma. / Chou, Tsung Han; Musada, Ganeswara Rao; Romano, Giovanni Luca; Bolton, Elizabeth; Porciatti, Vittorio.

In: International Journal of Molecular Sciences, Vol. 19, No. 1, 237, 13.01.2018.

Research output: Contribution to journalArticle

Chou, Tsung Han ; Musada, Ganeswara Rao ; Romano, Giovanni Luca ; Bolton, Elizabeth ; Porciatti, Vittorio. / Anesthetic preconditioning as endogenous neuroprotection in glaucoma. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 1.
@article{11c44efed1f748c7a7281404a173fbe6,
title = "Anesthetic preconditioning as endogenous neuroprotection in glaucoma",
abstract = "Blindness in glaucoma is the result of death of Retinal Ganglion Cells (RGCs) and their axons. RGC death is generally preceded by a stage of reversible dysfunction and structural remodeling. Current treatments aimed at reducing intraocular pressure (IOP) are ineffective or incompletely effective in management of the disease. IOP-independent neuroprotection or neuroprotection as adjuvant to IOP lowering in glaucoma remains a challenge as effective agents without side effects have not been identified yet. We show in DBA/2J mice with spontaneous IOP elevation and glaucoma that the lifespan of functional RGCs can be extended by preconditioning RGCs with retrobulbar lidocaine in one eye at four months of age that temporary blocks RGC axonal transport. The contralateral, PBS-injected eye served as control. Lidocaine-induced impairment of axonal transport to superior colliculi was assessed by intravitreal injection of cholera toxin B. Long-term (nine months) effect of lidocaine were assessed on RGC electrical responsiveness (PERG), IOP, expression of relevant protein (BDNF, TrkB, PSD95, GFAP, Synaptophysin, and GAPDH) and RGC density. While lidocaine treatment did not alter the age-related increase of IOP, TrkB expression was elevated, GFAP expression was decreased, RGC survival was improved by 35{\%}, and PERG function was preserved. Results suggest that the lifespan of functional RGCs in mouse glaucoma can be extended by preconditioning RGCs in early stages of the disease using a minimally invasive treatment with retrobulbar lidocaine, a common ophthalmologic procedure. Lidocaine is inexpensive, safe and is approved by Food and Drug Administration (FDA) to be administered intravenously.",
keywords = "Glaucoma, Lidocaine, Mouse, Neuroprotection, Retinal ganglion cells",
author = "Chou, {Tsung Han} and Musada, {Ganeswara Rao} and Romano, {Giovanni Luca} and Elizabeth Bolton and Vittorio Porciatti",
year = "2018",
month = "1",
day = "13",
doi = "10.3390/ijms19010237",
language = "English (US)",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Anesthetic preconditioning as endogenous neuroprotection in glaucoma

AU - Chou, Tsung Han

AU - Musada, Ganeswara Rao

AU - Romano, Giovanni Luca

AU - Bolton, Elizabeth

AU - Porciatti, Vittorio

PY - 2018/1/13

Y1 - 2018/1/13

N2 - Blindness in glaucoma is the result of death of Retinal Ganglion Cells (RGCs) and their axons. RGC death is generally preceded by a stage of reversible dysfunction and structural remodeling. Current treatments aimed at reducing intraocular pressure (IOP) are ineffective or incompletely effective in management of the disease. IOP-independent neuroprotection or neuroprotection as adjuvant to IOP lowering in glaucoma remains a challenge as effective agents without side effects have not been identified yet. We show in DBA/2J mice with spontaneous IOP elevation and glaucoma that the lifespan of functional RGCs can be extended by preconditioning RGCs with retrobulbar lidocaine in one eye at four months of age that temporary blocks RGC axonal transport. The contralateral, PBS-injected eye served as control. Lidocaine-induced impairment of axonal transport to superior colliculi was assessed by intravitreal injection of cholera toxin B. Long-term (nine months) effect of lidocaine were assessed on RGC electrical responsiveness (PERG), IOP, expression of relevant protein (BDNF, TrkB, PSD95, GFAP, Synaptophysin, and GAPDH) and RGC density. While lidocaine treatment did not alter the age-related increase of IOP, TrkB expression was elevated, GFAP expression was decreased, RGC survival was improved by 35%, and PERG function was preserved. Results suggest that the lifespan of functional RGCs in mouse glaucoma can be extended by preconditioning RGCs in early stages of the disease using a minimally invasive treatment with retrobulbar lidocaine, a common ophthalmologic procedure. Lidocaine is inexpensive, safe and is approved by Food and Drug Administration (FDA) to be administered intravenously.

AB - Blindness in glaucoma is the result of death of Retinal Ganglion Cells (RGCs) and their axons. RGC death is generally preceded by a stage of reversible dysfunction and structural remodeling. Current treatments aimed at reducing intraocular pressure (IOP) are ineffective or incompletely effective in management of the disease. IOP-independent neuroprotection or neuroprotection as adjuvant to IOP lowering in glaucoma remains a challenge as effective agents without side effects have not been identified yet. We show in DBA/2J mice with spontaneous IOP elevation and glaucoma that the lifespan of functional RGCs can be extended by preconditioning RGCs with retrobulbar lidocaine in one eye at four months of age that temporary blocks RGC axonal transport. The contralateral, PBS-injected eye served as control. Lidocaine-induced impairment of axonal transport to superior colliculi was assessed by intravitreal injection of cholera toxin B. Long-term (nine months) effect of lidocaine were assessed on RGC electrical responsiveness (PERG), IOP, expression of relevant protein (BDNF, TrkB, PSD95, GFAP, Synaptophysin, and GAPDH) and RGC density. While lidocaine treatment did not alter the age-related increase of IOP, TrkB expression was elevated, GFAP expression was decreased, RGC survival was improved by 35%, and PERG function was preserved. Results suggest that the lifespan of functional RGCs in mouse glaucoma can be extended by preconditioning RGCs in early stages of the disease using a minimally invasive treatment with retrobulbar lidocaine, a common ophthalmologic procedure. Lidocaine is inexpensive, safe and is approved by Food and Drug Administration (FDA) to be administered intravenously.

KW - Glaucoma

KW - Lidocaine

KW - Mouse

KW - Neuroprotection

KW - Retinal ganglion cells

UR - http://www.scopus.com/inward/record.url?scp=85040921821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040921821&partnerID=8YFLogxK

U2 - 10.3390/ijms19010237

DO - 10.3390/ijms19010237

M3 - Article

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 1

M1 - 237

ER -